Combined α2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat

International Journal of Neuropsychopharmacology

Volumn 8, Issue 3, 2005, Pages 315-327

  Marcus, Monica M ^a   Jardemark, Kent E ^a   Wadenberg, Marie Louise ^a,b   Langlois, Xavier ^c   Hertel, Peter ^d   Svensson, Torgny H ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LINNAEUS UNIVERSITY   (Sweden)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d H LUNDBECK A S   (Denmark)

Author keywords

2 adrenoceptors; Cognition; Dopamine; Glutamate; Schizophrenia

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2A ADRENERGIC RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; CLOZAPINE; DIZOCILPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; GLUTAMIC ACID; IDAZOXAN; NEUROLEPTIC AGENT; RACLOPRIDE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMINO ACID RECEPTOR BLOCKING AGENT; DIZOCILPINE MALEATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; COGNITIVE DEFECT; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; DRUG INDUCED DISEASE; DRUG POTENTIATION; ELECTROPHYSIOLOGY; EXCITATORY POSTSYNAPTIC POTENTIAL; GLUTAMATERGIC TRANSMSSION; MALE; MAZE TEST; MEMORY DISORDER; NEUROTRANSMISSION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT; RECEPTOR BLOCKING; SCHIZOPHRENIA; WORKING MEMORY; ANIMAL; ANIMAL BEHAVIOR; BRAIN CORTEX; COMPARATIVE STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG INTERACTION; ELECTROSTIMULATION; IN VITRO STUDY; METABOLISM; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RADIATION EXPOSURE; RADIOASSAY; SPRAGUE DAWLEY RAT; SYNAPTIC TRANSMISSION; WISTAR RAT;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; BEHAVIOR, ANIMAL; CEREBRAL CORTEX; CLOZAPINE; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTRIC STIMULATION; EXCITATORY AMINO ACID ANTAGONISTS; EXCITATORY POSTSYNAPTIC POTENTIALS; GLUTAMIC ACID; IDAZOXAN; MALE; MAZE LEARNING; RACLOPRIDE; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, DOPAMINE D2; SYNAPTIC TRANSMISSION;

EID: 22344444314     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145705005328     Document Type: Article

References (60)

1. Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, Hwang DR, Keilp J, Kochan L, Van Heertum R, Gorman JM, Laruelle M (2002). Prefrontal dopamine d1 receptors and working memory in schizophrenia. Journal of Neuroscience 22, 3708-3719.
2. Arnsten AF (2004). Adrenergic targets for the treatment of cognitive deficits in schizophrenia. Psychopharmacology 174, 25-31.
3. Arvanov VL, Liang X, Schwartz J, Grossman S, Wang RY (1997). Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. Journal of Pharmacology and Experimental Therapeutics 283, 226-234.
4. Arvanov VL, Wang RY (1997). NMDA-induced response in pyramidal neurons of the rat medial prefrontal cortex slices consists of NMDA and non-NMDA components. Brain Research 768, 361-364.
5. Arvanov VL, Wang RY (1998). M100907, a selective 5-HT2A receptor antagonist and a potential antipsychotic drug, facilitates N-methyl-D-aspartate- receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro. Neuropsychopharmacology 18, 197-209.
6. Ashby Jr. CR, Wang RY (1996). Pharmacological actions of the atypical antipsychotic drug clozapine: a review. Synapse 24, 349-394.
7. Aura J, Riekkinen Jr. P (1999). Blockade of NMDA receptors located at the dorsomedial prefrontal cortex impairs spatial working memory in rats. Neuroreport 10, 243-248.
8. Butelman ER (1989). A novel NMDA antagonist, MK-801, impairs performance in a hippocampal-dependent spatial learning task. Pharmacology, Biochemistry, and Behavior 34, 13-16.
9. Carboni E, Tanda GL, Frau R, Di Chiara G (1990). Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. Journal of Neurochemistry 55, 1067-1070.
10. Carlsson A, Lindqvist M, Magnusson T, Waldeck B (1958). On the presence of 3-hydroxytyramine in brain. Science 127, 471.
11. Castner SA, Williams GV, Goldman-Rakic PS (2000). Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science 287, 2020-2022.
12. Chen G, Greengard P, Yan Z (2004). Potentiation of NMDA receptor currents by dopamine D1 receptors in prefrontal cortex. Proceedings of the National Academy of Sciences USA 101, 2596-2600.
13. Chen L, Yang CR (2002). Interaction of dopamine D1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex. Journal of Neurophysiology 87, 2324-2336.
14. Connors BW, Gutnick MJ (1990). Intrinsic firing patterns of diverse neocortical neurons. Trends in Neurosciences 13, 99-104.
15. Coyle JT, Tsai G, Goff D (2003). Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Annals of the New York Academy of Science 1003, 318-327.
16. Darney Jr. KJ, Lewis MH, Brewster WK, Nichols DE, Mailman RB (1991). Behavioral effects in the rat of dihydrexidine, a high-potency, full-efficacy D1 dopamine receptor agonist. Neuropsychopharmacology 5, 187-195.
17. Davis JM, Chen N, Glick ID (2003). A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 60, 553-564.
18. De Paermentier F, Mauger JM, Lowther S, Crompton MR, Katona CL, Horton RW (1997). Brain alpha-adrenoceptors in depressed suicides. Brain Research 757, 60-68.
19. Devoto P, Flore G, Vacca G, Pira L, Arca A, Casu MA, Pani L, Gessa GL (2003). Co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex induced by clozapine, the prototype atypical antipsychotic. Psychopharmacology 167, 79-84.
20. Emamian ES, Karayiorgou M, Gogos JA (2004). Decreased phosphorylation of NMDA receptor type 1 at serine 897 in brains of patients with schizophrenia. Journal of Neuroscience 24, 1561-1564.
21. Friedman JI, Adler DN, Temporini HD, Kemether E, Harvey PD, White L, Parrella M, Davis KL (2001). Guanfacine treatment of cognitive impairment in schizophrenia. Neuropsychopharmacology 25, 402-409.
22. Goldman-Rakic PS, Muly III EC, Williams GV (2000). D(1) receptors in prefrontal cells and circuits. Brain Research Brain Research Reviews 31, 295-301.
23. Green MF (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry 153, 321-330.
24. Gresch PJ, Sved AF, Zigmond MJ, Finlay JM (1995). Local influence of endogenous norepinephrine on extracellular dopamine in rat medial prefrontal cortex. Journal of Neurochemistry 65, 111-116.
25. Hertel P, Fagerquist MV, Svensson TH (1999a). Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Science 286, 105-107.
26. Hertel P, Nomikos GG, Svensson TH (1999b). Idazoxan preferentially increases dopamine output in the rat medial prefrontal cortex at the nerve terminal level. European Journal of Pharmacology 371, 153-158.
27. Honey RA, Turner DC, Honey GD, Sharar SR, Kumaran D, Pomarol-Clotet E, McKenna P, Sahakian BJ, Robbins TW, Fletcher PC (2003). Subdissociative dose ketamine produces a deficit in manipulation but not maintenance of the contents of working memory. Neuropsychopharmacology 28, 2037-2044.
28. Izquierdo I (1991). Role of NMDA receptors in memory. Trends in Pharmacological Sciences 12, 128-129.
29. Jardemark KE, Ai J, Ninan I, Wang RY (2001). Biphasic modulation of NMDA-induced responses in pyramidal cells of the medial prefrontal cortex by Y-931, a potential atypical antipsychotic drug. Synapse 41, 294-300.
30. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry 148, 1301-1308.
31. Kane J, Honigfeld G, Singer J, Meltzer H (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 45, 789-796.
32. Kolb B, Pittman K, Sutherland RJ, Whishaw IQ (1982). Dissociation of the contributions of the prefrontal cortex and dorsomedial thalamic nucleus to spatially guided behavior in the rat. Behavioural Brain Research 6, 365-378.
33. Lacroix LP, Hows ME, Shah AJ, Hagan JJ, Heidbreder CA (2003). Selective antagonism at dopamine D3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex. Neuropsychopharmacology 28, 839-849.
34. Langlois X, te Riele P, Wintmolders C, Leysen JE, Jurzak M (2001). Use of the beta-imager for rapid ex vivo autoradiography exemplified with central nervous system penetrating neurokinin 3 antagonists. Journal of Pharmacology and Experimental Therapeutics 299, 712-717.
35. Levin ED, Bettegowda C, Weaver T, Christopher NC (1998). Nicotine-dizocilpine interactions and working and reference memory performance of rats in the radial-arm maze. Pharmacology, Biochemistry, and Behavior 61, 335-340.
36. Levin ED, Sledge D, Baruah A, Addy NA (2003). Ventral hippocampal NMDA blockade and nicotinic effects on memory function. Brain Research Bulletin 61, 489-495.
37. Levine MS, Altemus KL, Cepeda C, Cromwell HC, Crawford C, Ariano MA, Drago J, Sibley DR, Westphal H (1996). Modulatory actions of dopamine on NMDA receptor-mediated responses are reduced in D1A-deficient mutant mice. Journal of Neuroscience 16, 5870-5882.
38. Litman RE, Su TP, Potter WZ, Hong WW, Pickar D (1996). Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. British Journal of Psychiatry 168, 571-579.
39. McCormick DA, Connors BW, Lighthall JW, Prince DA (1985). Comparative electrophysiology of pyramidal and sparsely spiny stellate neurons of the neocortex. Journal of Neurophysiology 54, 782-806.
40. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S (2003). Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Archives of General Psychiatry 60, 82-91.
41. Meltzer HY, McGurk SR (1999). The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin 25, 233-255.
42. Mohn AR, Gainetdinov RR, Caron MG, Koller BH (1999). Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98, 427-436.
43. Molderings GJ, Donecker K, Burian M, Simon WA, Schroder DW, Gothert M (1998). Characterization of 12 imidazoline and sigma binding sites in the rat and human stomach. Journal of Pharmacology and Experimental Therapeutics 285, 170-177.
44. Ninan I, Jardemark KE, Wang RY (2003). Differential effects of atypical and typical antipsychotic drugs on N-methyl-D-aspartate and electrically evoked responses in the pyramidal cells of the rat medial prefrontal cortex. Synapse 48, 66-79.
45. Ninan I, Wang RY (2003). Modulation of the ability of clozapine to facilitate NMDA and electrically evoked responses in pyramidal cells of the rat medial prefrontal cortex by dopamine: pharmacological evidence. European Journal of Neuroscience 17, 1306-1312.
46. Olton DS (1979). Mazes, maps, and memory. American Psychologist 34, 583-596.
47. Phillips AG, Ahn S, Floresco SB (2004). Magnitude of dopamine release in medial prefrontal cortex predicts accuracy of memory on a delayed response task. Journal of Neuroscience 24, 547-553.
48. Pozzi L, Invernizzi R, Cervo L, Vallebuona F, Samanin R (1994). Evidence that extracellular concentrations of dopamine are regulated by noradrenergic neurons in the frontal cortex of rats. Journal of Neurochemistry 63, 195-200.
49. Robert F, Bert L, Lambas-Senas L, Denoroy L, Renaud B (1996). In vivo monitoring of extracellular noradrenaline and glutamate from rat brain cortex with 2-min microdialysis sampling using capillary electrophoresis with laser-induced fluorescence detection. Journal of Neuroscience Methods 70, 153-162.
50. Ruggiero DA, Regunathan S, Wang H, Milner TA, Reis DJ (1998). Immunocytochemical localization of an imidazoline receptor protein in the central nervous system. Brain Research 780, 270-293.
51. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124, 57-73.
52. Siegel S, Castellan Jr. NJ (1988). Nonparametric Statistics for the Behavioral Sciences. New York: McGraw-Hill.
53. Svensson TH (2000). Brain noradrenaline and the mechanisms of action of antidepressant drugs. Acta Psychiatrica Scandinavica Supplementum 402, 18-27.
54. 3H]RS79948-197 binding to human, rat, guinea pig and pig alpha2A-, alpha2B- and alpha2C-adrenoceptors. Comparison with MK912, RX821002, rauwolscine and yohimbine. European Journal of Pharmacology 343, 93-101.
55. Wadenberg ML, Kapur S, Soliman A, Jones C, Vaccarino F (2000). Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology 150, 422-429.
56. Wadenberg M-LG, Soliman A, VanderSpek SC, Kapur S (2001). Dopamine d(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 25, 633-641.
57. Ward L, Mason SE, Abraham WC (1990). Effects of the NMDA antagonists CPP and MK-801 on radial arm maze performance in rats. Pharmacology, Biochemistry, and Behavior 35, 785-790.
58. Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK, Berman KF, Goldberg TE (2001). Prefrontal neurons and the genetics of schizophrenia. Biological Psychiatry 50, 825-844.
59. Yang CR, Seamans JK, Gorelova N (1996). Electrophysiological and morphological properties of layers V-VI principal pyramidal cells in rat prefrontal cortex in vitro. Journal of Neuroscience 16, 1904-1921.
60. Zheng P, Zhang XX, Bunney BS, Shi WX (1999). Opposite modulation of cortical N-methyl-D-aspartate receptor-mediated responses by low and high concentrations of dopamine. Neuroscience 91, 527-535.